Stifel Nicolaus surveyed 35 hematology/oncology specialists, and the firm now believes that the survey indicates that ARIAD’s ponatinib in front-line CML showed significant potential. The firm believes that the company’s outlook for the drug’s selling continues to be conservative, and it keeps its Buy rating on the stock.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.